EP3769753A1 - Verfahren zur herstellung steriler ophthalmischer wässriger fluticasonpropionat-nanokristallsuspensionen - Google Patents

Verfahren zur herstellung steriler ophthalmischer wässriger fluticasonpropionat-nanokristallsuspensionen Download PDF

Info

Publication number
EP3769753A1
EP3769753A1 EP20186965.8A EP20186965A EP3769753A1 EP 3769753 A1 EP3769753 A1 EP 3769753A1 EP 20186965 A EP20186965 A EP 20186965A EP 3769753 A1 EP3769753 A1 EP 3769753A1
Authority
EP
European Patent Office
Prior art keywords
fluticasone propionate
nanocrystals
nanosuspension
phase
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20186965.8A
Other languages
English (en)
French (fr)
Other versions
EP3769753B1 (de
Inventor
Jean-Michel BUKOWSKI
Akshay NADKARNI
José L. BOYER
Brigitte DUQUESROIX-CHAKROUN
Tomas Navratil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox Ophthalmics Inc
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Priority to HRP20220165TT priority Critical patent/HRP20220165T1/hr
Priority to PL20186965T priority patent/PL3769753T3/pl
Priority to RS20220142A priority patent/RS62932B1/sr
Priority to SI202030032T priority patent/SI3769753T1/sl
Publication of EP3769753A1 publication Critical patent/EP3769753A1/de
Application granted granted Critical
Publication of EP3769753B1 publication Critical patent/EP3769753B1/de
Priority to CY20221100069T priority patent/CY1124930T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Definitions

  • the present invention relates to a process for the preparation of sterile topical ophthalmic nanosuspensions containing nanocrystals of fluticasone propionate Form A in an aqueous vehicle.
  • This process is readily adaptable to preparation for large-scale production and leads to sterile homogeneous aqueous nanosuspensions having a stable particle size distribution.
  • the sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals are useful in the treatment of eye inflammation diseases or eye inflammatory conditions through topical administration of said nanosuspensions (or nanocrystals suspensions) to eyelids (e.g. upper and lower lids), eyelashes and eyelid margin.
  • Nanocrystals of fluticasone propionate Form A are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.
  • the fluticasone propionate Form A nanocrystals are prepared from a commercially available fluticasone propionate polymorph 1 by the anti-solvent sonocrystallization process disclosed in WO 2013/169647 .
  • WO 2013/169647 discloses the preparation of nanocrystals of a morphic form of fluticasone propionate (Form A), their purification and also the preparation of the aqueous suspensions containing said nanocrystals.
  • the nanocrystals of fluticasone propionate are prepared using antisolvent crystallization under sonication followed by the thermal annealing of the nanosuspension; the generated nanocrystals are purified by continuous flow centrifugation, the vehicle of the nanosuspension is centrifuged out, the pellet is re-dispersed in the washing solution and the dispersion centrifuged again. This washing procedure is repeated several times to achieve the desired level of purification. The pellet is then dispersed into the final formulation composition to obtain the final product at required dose strength.
  • WO 2013/169647 does not report any data related to the sterility tests of the nanosuspension.
  • nanosuspensions exhibited some propensity to reaggregate and to be unstable.
  • nanoparticles have a high propensity to agglomerate due to their high surface energy that cause the formation of agglomerates during the preparation and storage of the nanosuspensions,
  • Aggregation of the nanoparticles is not only a critical aspect during the manufacturing of the suspensions; agglomeration can cause a variety of issues, for example, inconsistent dosing and patient non-compliance.
  • agglomeration may impact the tolerability in patients and potential safety.
  • stabilizers are usually used, however, the selection of an appropriate stabilizer for a certain drug can be challenging.
  • US 2018/0117064 discloses the preparation of aqueous suspensions containing nanoparticles of a glucocorticosteroid compound and a dispersion stabilizer. US 2018/0117064 discloses that the main function of the stabilizer is to wet the drug particles thoroughly to prevent Ostwald ripening and agglomeration of the nanosuspension and to form a physically stable formulation by providing asteric or an ionic barrier.
  • Typical examples of stabilizers used in nanosuspensions are celluloses, poloxamer, polysorbates, lecithin, polyoleate and povidones.
  • WO 2010/141834 discloses topical ophthalmic formulations of fluticasone propionate for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis.
  • WO 2010/141834 discloses a variety of formulations including suspensions having a particle size no greater than 30 ⁇ m; an example of vehicle comprises phosphate buffer, propylene glycol, hypromellose, polysorbate 80, edetate disodium and benzalkonium chloride (page 14, lines, 7-15).
  • WO 2010/141834 does not report any method of preparation of the ophthalmic formulations and any experimental results related to the stability of the ophthalmic formulations.
  • WO 2013/025696 discloses the use of high pressure homogenization to prevent formation of drug aggregates in an ophthalmic formulation containing an ophthalmic drug suspended in an aqueous vehicle containing at least one wetting agent.
  • the high pressure homogenization step may be used to prevent the formation of drug aggregates in the ophthalmic formulation when the drug particles are already present in a micronized form having particle sizes suitable for topical application; indeed WO 2013/025696 discloses that the high pressure homogenization may be applied to a suspension containing the pre-micronized drug in the aqueous solution of wetting agent and the high pressure homogenization does not bring about particle size reduction but instead stabilizes the already micronized drug, and thus prevent the formation of drug aggregates.
  • the sonication process is commonly used for deagglomerating and dispersing nanomaterials in aqueous based media, necessary to improve homogeneity and stability of the suspension.
  • sonication treatment tested during the setting up of the process for the preparation of the nanosuspensions of the present invention was not effective to deagglomerate fluticasone propionate nanocrystals.
  • boric acid-polyol complexes Complexes of boric acid with polyhydroxyl compounds (borate-polyol complexes) are well known and it is generally known the use of borate-polyol complexes in ophthalmic composition to enhance antimicrobial activity.
  • WO 93/21903 discloses borate-polyol complexes, such as mannitol, glycerol and propylene glycol, as adjunctive disinfecting agent in contact lens disinfecting solutions.
  • WO 2010/148190 discloses borate-polyol complexes including two different polyols to improve preservation of multi-dose ophthalmic compositions.
  • the present invention relates to a process for the preparation of sterile topical ophthalmic aqueous suspensions containing fluticasone propionate Form A nanocrystals that is readily adaptable to large-scale preparation for commercial production and gives rise to stable nanosuspensions with a homogenous reproducible particle size distribution.
  • fluticasone propionate Form A nanocrystals refer to fluticasone propionate Form A nanocrystals that have mean particle size from 100 nm to 1000 nm, a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2 ⁇ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2 ⁇ , and wherein the said nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates.
  • the present invention relates to a process for the preparation of sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm and a concentration of fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:
  • step c) the high-shear, high speed mixing of the slurry containing the nanocrystals of fluticasone propionate form A and the aqueous vehicle 1, which does not contain glycerin, is conducted to ensure an even distribution of the fluticasone propionate nanocrystals to improve the homogeneity of the final nanosuspension.
  • step c) and in step f) the high-shear, high-speed mixing is performed at 6000 RPM.
  • step f) Preferably the high-shear, high-speed mixing of step f) is applied for at least 10 minutes.
  • step g) of the nanosuspension of step f) containing a concentration of fluticasone propionate of 1% w/w is performed by autoclaving the nanosuspension in glass bottles at about 122 °C for about 40 minutes.
  • aqueous vehicles 1 and 2 are filtered through 0.2 ⁇ m filter before their use in step b) and step e) respectively.
  • the aqueous vehicle 2 containing glycerin 1.8% w/w may be prepared by adding to an aliquot of vehicle 1 filtered through 0.2 ⁇ m filter an amount of glycerin to obtain a final concentration of glycerin of 1.8% w/w.
  • the concentration of fluticasone propionate is from 0.001% to 0.5% w/w; more preferably the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; most preferably the concentration of fluticasone propionate is 0.20% w/w or 0.10% w/w or 0.05% w/w.
  • the process of the present invention may be performed under fully aseptic manufacturing conditions utilizing sterilized Fluticasone propionate Form A nanocrystals and sterilized vehicles 1 to 3, accordingly another embodiment of the present invention relates to a process for the preparation of sterile topical ophthalmic aqueous nanosuspensions containing fluticasone propionate Form A nanocrystals having a mean particle size from 100 nm to 1000 nm and a concentration of fluticasone propionate from 0.001% w/w to 1% w/w, said process comprises:
  • the fluticasone propionate Form A nanocrystals used in step a-1) are sterilized by autoclaving a suspension of fluticasone propionate Form A nanocrystals in water for injection having a concentration of fluticasone propionate between 2 % to 20 % w/w; preferably the suspension of fluticasone propionate Form A nanocrystals in water is autoclaved at about 122 °C for about 30 minutes.
  • step d-1) and step g-1) the high-shear, high-speed mixing is performed at 6000 RPM.
  • step g-1 Preferably the high-shear, high-speed mixing of step g-1) is applied for at least 10 minutes.
  • the concentration of fluticasone propionate is from 0.001% to 0.5% w/w; more preferably the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; most preferably 0.20% w/w or 0.10% w/w or 0.05% w/w.
  • fluticasone propionate Form A nanocrystals used in the process of the present invention are prepared according to a general method reported below that comprises the following steps:
  • the washed nanocrystal of step 10 are sterilized before their use for the preparation of the sterile topical ophthalmic aqueous nanosuspensions; for example, the washed nanocrystals are suspended in water for injection at a fluticasone propionate concentration between 2 % to 20 % w/w, and autoclaved at about 122 °C for 30 minutes.
  • Another embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and consisting of:
  • the concentration of fluticasone propionate is from 0.001% to 0.5% w/w, more preferably the concentration of fluticasone propionate is 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.1% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w. Most preferably in the topical ophthalmic aqueous nanosuspension the concentration of fluticasone propionate is 0.1% w/w, 0.20% w/w or 0.05% w/w.
  • Another embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and consisting of:
  • Another preferred embodiment of the present invention relates to an ophthalmic aqueous nanosuspension administrable topically onto eyelids, eyelashes or eyelid margin and consisting of:
  • the sterile topical ophthalmic aqueous nanosuspensions prepared according to the process of the present invention have some advantages, for example better tolerability upon administration onto eyelids (e.g. the upper and lower eyelids), eyelashes or eyelid margin due to the small particles sizes and maintenance of drug release over a prolonged period of time that allows reducing the amount of the active principle to be administered and, consequently, reducing the systemic exposure to fluticasone propionate as well as reducing the exposure to other structure of the eye.
  • corticosteroids have side effects such as the increase of the intra-ocular pressure (IOP), the increase of corneal thickness, mydriasis, ptosis, cataract, glaucoma, adrenal suppression, decrease in bone mineral density; therefore low systemic exposure an overall eye are an important advantages of the ophthalmic aqueous nanosuspensions prepared according to the process of the present invention in particular for therapeutic applications that require long-term or repetitive corticosteroid treatment.
  • IOP intra-ocular pressure
  • the sterile topical ophthalmic aqueous nanosuspension of the present invention has high efficacy and local tolerability without the unwanted side-effects associated with the systemic absorption of the fluticasone propionate active ingredient.
  • the nanosuspension of the present invention may be used in a method for treating or reducing the symptoms and/or clinical signs associated with eye inflammation diseases or eye inflammatory conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease by topical administration of said composition to the eye lids, eye lashes or eye lid margin of a subject in need.
  • Such method for treating blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease comprises the step of topically administering to a subject's eyelids, eyelashes or eyelid margin an effective amount of the nanosuspension of the present invention.
  • Another embodiment of the invention provides a method of treatment and or reducing the symptoms and/or clinical signs associated with blepharitis, posterior blepharitis, Meibomian gland dysfunction or dry eye disease, the method comprising administering an effective amount of a pharmaceutical composition to a subject in need thereof wherein the pharmaceutical composition is an ophthalmic aqueous nanosuspension consisting of: 0.001% to 1% w/w nanocrystals of fluticasone propionate Form A, 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid, 0.9% w/w glycerin, 0.01% w/w benzalkonium chloride, 0.055% w/w sodium chloride, hydrochloric acid IN and / or sodium hydroxide IN as adjusting agents in an amount sufficient pH from 7.3-7.5, and water q.s.
  • nanocrystals of fluticasone propionate Form A have a mean particle size from 100 nm to 1000 nm and a X-ray powder diffraction pattern including peaks at about 7.8, 15.7, 20.8, 23.7, 24.5, and 32.5 degrees 2 ⁇ , further including peaks at about 9.9, 13.0, 14.6, 16.0, 16.9, 18.1, and 34.3 degrees 2 ⁇ , and wherein the nanocrystals are nanoplates having the [001] crystallographic axis substantially normal to the surfaces that define the thickness of the nanoplates, wherein the ophthalmic aqueous nanosuspension is administered topically to the upper and/or lower eye lid margins, Meibomian gland ducts eyelashes or any area of the eye lid anatomy.
  • the ophthalmic aqueous nanosuspension used in the method of the invention contain a concentration of fluticasone propionate Form A nanocrystals of 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.10% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w or 0.005% w/w; more preferably the concentration of fluticasone propionate Form A nanocrystals in the ophthalmic aqueous nanosuspension is of 0.1% w/w, 0.20% w/w 0.25% w/w, 0.5% w/w, 0.05% w/w or 0.01% w/w; most preferably the concentration of fluticasone propionate Form A nanocrystals is 0.1% w/w, 0.20% w/w or 0.05% w/w.
  • Typical clinical signs associated with blepharitis and Meibomian gland dysfunction include lid debris, redness of eyelid margin, eyelid swelling, obstruction of the Meibomian gland, and or qualitative/quantitative changes in Meibomian gland secretion.
  • the most common symptoms associated with dry eye which is also known as keratoconjunctivitis sicca, include eye dryness, eye discomfort, eye redness, a stinging, burning or scratchy sensation in the eyes, watery eyes, sensitivity to light, blurred vision, pain or eye fatigue.
  • the method of the invention is preferably directed to a method for treating non-infectious, inflammatory blepharitis or Meibomian gland dysfunction in a subject.
  • a subject is administered with topical ophthalmic aqueous nanosuspension of the present invention at least once a day, preferably subject is administered with the pharmaceutical formulation once a day.
  • a subject is administered with topical ophthalmic aqueous nanosuspension of the present invention at least once a day for at least two weeks, more than two weeks, at least three weeks, or at least four weeks.
  • kits comprising (a) the above reported topical administrable ophthalmic aqueous nanosuspension containing fluticasone propionate Form A nanocrystals and (b) a swab or sponge to apply the nanosuspension to the eyelids, eyelashes or eyelid margin.
  • an initial quantity of about 5276 g of purified water was added and stirred with an over-head mixer so that a vortex was generated.
  • Phase II was then filtered using a 0.8/0.2 ⁇ m Polyethersulfone (PES) filter and kept refrigerated at 2-8°C until use.
  • PES Polyethersulfone
  • phase II 480g of phase II were introduced into the chamber of the reactor. 940 g phase I and 3780 g phase II were allowed to cool down to a target temperature of 2-4 °C in their jacketed vessels connected to chillers.
  • phase I and phase II were pumped (pump flow rates for phase I and phase II were respectively 600 ml/min and 2400 ml/min) through the reactor fitted with its ultrasonic transducer with an amplitude set at 60% (Q Sonica Q1375 W).
  • phase III 5201.7 g
  • the temperature of phase III was about 11°C.
  • phase III was stirred at room temperature for about 30 minutes in the collecting vessel to obtain a uniform suspension of fluticasone propionate nanocrystals (final phase III).
  • the final phase III was transferred into a closed container.
  • the container was placed in an incubator and maintained at 40°C for at least 16 hours.
  • phase III 5167 g of the annealed phase III were transferred into a process vessel and an equivalent amount of dilution buffer solution was added, so that the ratio of phase III to dilution buffer solution was 1: 1.
  • the resulting mixture was stirred with a low shear mixer for 30 minutes to achieve a homogeneous suspension of nanocrystals (diluted phase III).
  • the diluted phase III was kept refrigerated at 2-8°C until centrifugation.
  • the fluticasone propionate Form A nanocrystals were first collected by discontinuous centrifugation of the diluted phase III. The nanocrystals were then washed several times (4 washing cycles) with water for injection.
  • the particle size of the isolated nanocrystals was evaluated using a laser scattering Particle size distribution analyzer (Horiba LA-950).
  • the D 50 was 0.2153 ⁇ m and the D 90 was 0.6073 ⁇ m
  • Table 1 Fluticasone propionate nanosuspension composition Ingredients Amount (% w/w) Fluticasone propionate Form A nanocrystals 0.10 Methylcellulose 4000 cP 0.50 Polysorbate 80 0.2 Edetate disodium, dihydrate 0.10 Boric acid 1.0 Glycerin 0.9 Benzalkonium chloride 0.01 Sodium chloride 0.055 Water for injection q.s. to 100 % pH 7.3 - 7.5
  • Step 1) Preparation of vehicle 1 (vehicle without glycerin)
  • the solution was cooled at 40°C, 200.0 g boric acid was added and the pH was adjusted at 7.4 with sodium hydroxide (IN).
  • excipients were added in the specific following order: 20.0 g edetate disodium dihydrate, 11.0 g sodium chloride, 4.0 g benzalkonium chloride (solution 50%), 40.0 g polysorbate 80 (Tween 80); each excipient being fully dissolved before adding the next excipient and the preparation of the solution is carried out at a temperature of about 40°C to room temperature.
  • the pH was tested and optionally adjusted at 7.3 - 7.5 with hydrochloric acid (IN) or sodium hydroxide (IN); after the pH adjustment, water for injection was added to bring the final weight to 19800 g.
  • the resulting solution was mixed for at least 10 minutes to obtain a uniform solution which was stored at 2-8°C.
  • Step 3 Preparation of vehicle 2 (vehicle containing glycerin 1.8% w/w)
  • the 1% fluticasone propionate nanocrystals slurry was prepared by further diluting the 2% concentrated slurry prepared in Step 2) with vehicle 2 down to a concentration of fluticasone propionate of 1% w/w.
  • the 1% w/w fluticasone propionate Form A nanocrystals slurry was subject to high-shear, high-speed mixing at 6000 ⁇ 10 RPM for 10 minutes and the particle size distribution was tested by laser diffraction using a Horiba LA-950S2 PSD analyzer.
  • Step 5 Preparation of vehicle 3 (vehicle containing glycerin 0.9% w/w)
  • Step 6 Preparation of the 0.1% w/w fluticasone propionate nanosuspension.
  • the weight of the 1% fluticasone propionate nanocrystals slurry transferred in the vessel was recorded (1366.3g).
  • the final 0.1% sterile fluticasone propionate nanocrystal suspension was obtained by adding 11774.2g of the sterile vehicle 3.
  • the final sterile nanosuspension was stirred for not less than 15 minutes on a stir plate.
  • the particle size distribution was tested by laser diffraction using a Horiba LA-950S2 PSD analyzer.
  • Nanosuspensions according to the invention containing different concentrations of fluticasone propionate form A such as 0.5% w/w, 0.25% w/w, 0.20% w/w, 0.1% w/w, 0.05% w/w, 0.03% w/w, 0.01% w/w and 0.005% w/w were obtained by diluting the de-agglomerated 1% fluticasone propionate nanosuspension of step 4) with aliquots of aqueous vehicle 3 as disclosed in step 6) to obtain the final fluticasone propionate concentration.
  • the nanosuspension composition prepared in example 2 was subjected to storage stability testing by storing the nanosuspension at three different temperatures and humidity conditions (5°C, 25°C / 40% RH; 40°C / 25% RH)
  • the resuspendability of the nanosuspension, the content of fluticasone propionate, the particle size distribution and the content of benzalkonium chloride were assessed at 1 month and 3-month time-points.
  • Fluticasone propionate Form A nanocrystals were suspended in a vehicle containing the exact same concentrations of boric acid and of methylcellulose as in the previous Example 2 but it does not contain glycerol.
  • compositions of the tested nanosuspensions are reported in Table 4.
  • Table 4 Tested nanosuspensions Ingredient Concentration (% w/w) Fluticasone Propionate 0.1 0.03 0.01 0.005 N/A Methylcellulose 4000cP 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Polysorbate 80 (Tween 80) 0.2 0.2 0.2 0.2 0.2 Edetate disodium, dihydrate 0.1 0.1 0.1 0.1 0.1 0.1 Boric acid 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Sodium chloride 0.055 0.055 0.055 0.055 Glycerin 0 0 0 0 0 0 Benzalkonium chloride 0.01 0.01 0.01 0.01 0.01 Water for Injection q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100
  • An amount of Fluticasone propionate Form A nanocrystals were suspended in aliquots of vehicle consisting of: 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid; 0.01% w/w benzalkonium chloride and water q.s to 100% w/w (see Table 4), to get the targeted concentrations of fluticasone propionate (see Table 4).
  • the suspension was poured into a 500mL glass beaker for deagglomeration using a high-speed, high-shear Silverson mixing apparatus. The suspension was mixed at 6000 RPM until particle size distribution specifications were met. The particle size distribution and the viscosity of the nanosuspensions were measured.
  • the nanosuspensions were placed on stability at 40°C, the particle size distribution (PDS) and the viscosity were measured at 2-week time point.
  • Fluticasone propionate Form A nanocrystals were suspended and de-agglomerated in the vehicle containing the pre-formed boric acid/glycerol complex (boric acid 1.0% w/w /glycerol 0.25% w/w and boric acid 1.0% w/w /glycerol 1.0% w/w) to get a final concentration of Fluticasone propionate of 0.25% w/w.
  • compositions of the vehicles of the two tested nanosuspensions are reported in Table 6.
  • Table 6 Tested nanosuspensions Ingredient Concentration (% w/w) Fluticasone Propionate 0.25 0.25 Methylcellulose 4000cP 0.5 0.5 Tween 80 0.2 0.2 EDTA disodium, dihydrate 0.1 0.1 Boric acid 1.0 1.0 Sodium chloride 0.05 0.05 Glycerol 0.25 1.0 Benzalkonium chloride 0.01 0.01 Water for Injection q.s. to 100 q.s. to 100
  • Fluticasone propionate Form A nanocrystals were suspended in the two vehicles reported in Table 6 that contain the pre-formed boric acid / glycerol complex and stirred overnight on a magnetic stir plate, using a stir bar. Once the nanocrystals were suspended, the suspension was poured into a 500mL glass beaker for de-agglomeration using a high-speed, high-shear, Silverson mixing apparatus. The suspension was mixed at 6000 RPM until particle size distribution specifications were met.
  • thermo-reversible aggregation was related to the decrease of the solubility of the methylcellulose when the temperature increases. It is known that even though methylcellulose solutions are visually clear with no detectable particles in the range of 30-50 °C, the polymer chains form loosely-associated clusters that grow in size as the temperature increases. These clusters are likely responsible for part of the aggregation of the nanocrystals at 40°C.
  • glycerol acts as a stabilizer by forming a complex with the boric acid that prevents the aggregation of the isolated nanocrystals. If the nanosuspension is prepared by suspending the nanocrystals in the vehicle that contains the pre-formed complex boric acid / glycerol, the stabilizing effect of the complex is reduced.
  • the dissolution rate of the Fluticasone propionate form A nanocrystals of the nanosuspension of the invention was assessed and compared to the dissolution rate of a standard Fluticasone propionate form 1 micronized material (reference sample).
  • Dissolution profiles of nanocrystals of Fluticasone propionate form A of two nanosuspensions of the invention and of Fluticasone propionate form 1 micronized were performed using a dissolution method.
  • the particle size of the Fluticasone propionate Form A nanocrystals is 0.434 ⁇ m (D50 - median) and the particle size of the Fluticasone propionate form 1 micronized material is 4.64 ⁇ m (D50 - median).
  • the study was performed using a compartment diffusion analysis through a dialysis membrane and sink condition.
  • the sink condition was achieved through the use of a receptor fluid containing 30mM phosphate buffer, pH 7.4 with 5% HP ⁇ CD cyclodextrins and also by a complete replacement of the buffer every 24 hours to stay below the saturation point.
  • the saturation point was estimated to be 5 ⁇ g/g under those experimental conditions and the measurements performed as well as the buffer replacement have shown a maximum concentration of 1.5 ⁇ g/g.
  • the study was conducted at a temperature of 37°C.
  • Fluticasone propionate form 1 micronized was suspended in the same phosphate buffer used in the receiving compartment of the dialysis system.
  • Fluticasone propionate release was carried at 1-2 RPM.
  • the solubility of a compound is often intrinsically related to the particle size, as a particle becomes smaller, the surface area to volume ratio increases leading to greater interaction with the solvent which causes an increase in solubility
  • the results of this study show the unique property of the ophthalmic aqueous fluticasone propionate Form A nanocrystals of the invention, namely on one hand the small particle size (nanoparticles) improves the comfort and the tolerability of the ophthalmic formulation, on the other hand the slow dissolution rate of the fluticasone propionate active principle allows to avoid a fast and high absorption of fluticasone propionate correlated to the unwanted side-effects associated with the systemic absorption of the steroid.
  • Table 7 Dissolution test of Fluticasone propionate form A nanocrystals Time point (h) % Dissolution Tube #1 Tube #2 Tube #3 Average % St.
  • RSD 1 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 3 0.2% 1.4% 0.7% 0.8% 0.6% 73.2% 5 1.3% 2.8% 2.4% 2.2% 0.8% 35.6% 19 14.5% 20.4% 18.7% 17.8% 3.0% 16.9% 24 17.5% 24.0% 22.4% 21.3% 3.4% 15.9% 48 38.7% 51.4% 48.6% 46.2% 6.7% 14.4% 72 59.6% 78.1% 74.0% 70.5% 9.7% 13.7%
  • Table 8 Dissolution test of Fluticasone propionate form A nanocrystals Time point (h) % Dissolution Tube #1 Tube #2 Tube #3 Average % St.
  • Table 10 Test formulations composition Ingredient % (w/w) % (w/w) % (w/w) % (w/w) % (w/w) Fluticasone Propionate 0.00 0.005 0.03 0.1 Methylcellulose 4000cP 0.50 0.50 0.50 0.50 Tween 80 0.20 0.20 0.20 0.20 Edetate disodium, dihydrate 0.10 0.10 0.10 0.10 Boric acid 1.00 1.00 1.00 1.00 1.00 Sodium chloride 0.055 0.055 0.055 0.055 Glycerol 0.90 0.90 0.90 Benzalkonium chloride 0.01 0.01 0.01 0.01 0.01 Water for Injection q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100 q.s. to 100
  • Ophthalmology examinations were performed prior to treatment initiation, during the first and second weeks of dosing and during the last week of recovery. Eyes were scored once daily according to the modified Draize scale.
  • the group mean plasma toxicokinetic parameters are summarized in Table 11 below.
  • Table 11 Plasma Toxicokinetic Parameters of Fluticasone Propionate following topical ocular eyelid margin administration Study Day Ocular Treatment Dose ( ⁇ g/day) Tmax (h) Cmax (pg/mL) AUC 0 -24h (pg.h/mL) 1 0.005% QD 1.6 0.5 32.4 ⁇ 26.4 25.7 ⁇ 18.5 0.03% QD 9.6 0.5 79.8 ⁇ 70.0 101 ⁇ 102 0.1% QD 32 0.5 250 ⁇ 219 482 ⁇ 407 0.1% BID 64 6.5 304 ⁇ 178 914 ⁇ 413 14 0.005% QD 1.6 0.75 28.1 ⁇ 26.6 56.8 ⁇ 65.0 0.03% QD 9.6 0.5 60.8 ⁇ 48.7 191 ⁇ 335 0.1% QD 32 0.5 130 ⁇ 155 481 ⁇ 361 0.1% BID 64 0.5 126 ⁇ 93.6 760 ⁇ 188
  • the objective of this study was to compare the efficacy and safety of an aqueous ophthalmic formulation of Fluticasone propionate form A nanosuspension of the invention versus placebo in reducing signs and symptoms in subjects with blepharitis.
  • 0.1% w/w fluticasone propionate Form A nanocrystals (mean particle size from 100 nm to 1000 nm) 0.50% w/w methylcellulose 4000 cp, 0.2% w/w polysorbate 80, 0.10% w/w edetate disodium dihydrate, 1.0 % w/w boric acid, 0.9% w/w glycerin, 0.01% w/w benzalkonium chloride, 0.055% w/w sodium chloride, hydrochloric acid (IN) and/or sodium hydroxide (IN) as adjusting agents in an amount sufficient for pH from 7.3-7.5, and water q.s. to 100% w/w.
  • the target population in this study was adult men and women with a documented history of blepharitis who were experiencing an acute blepharitis exacerbation defined as a minimum score of '1' (on a 4-point scale) for each of Eyelid Margin Redness, Eyelid Debris, and Eyelid Discomfort in both eyes at the Screening and Baseline Visits. A total of 15 subjects were included in the study. Subject ages were between 55 and 80 years old, with an average age of 70.8 years.
  • Study visits were as follows: Screening (Day -7 to -3), Baseline/Day 1, Day 4 ( ⁇ 1 day), Day 8 ( ⁇ 1 day), Day 11 ( ⁇ 1 day), Day 14 (- 1 day; last day of treatment), and Day 28/Exit ( ⁇ 2 days; follow up visit).
  • Test nanosuspension (16 ⁇ g of fluticasone propionate per eye) or placebo were applied once a day in the evening. Study drug was self-administered by the subjects.
  • Efficacy and safety of fluticasone propionate form A nanosuspension were compared with placebo at each post-dose visit during the study.
  • this study evaluated signs and symptoms characteristic of dry eye disease, also commonly observed in subjects with blepharitis.
  • Tables 12 and 13 are related to signs and symptoms of blepharitis in the study eye evaluated after 14 days of treatment and conducted prior to daily eyelid scrub procedures.
  • VAS Visual Analog Scales
  • the treatment with fluticasone propionate Form A nanosuspension of the invention was very well tolerated, all patients completed the treatment. There were no Serious Adverse Events (SAEs) and in particular, no clinically relevant changes in subject's intraocular pressure were observed during treatment or up to two weeks after treatment discontinuation.
  • SAEs Serious Adverse Events
  • Table 13 Composite score of Eyelid Margin Redness, Eyelid Debris, and Eyelid Discomfort at 14 Day of treatment with fluticasone propionate form A nanosuspension of the invention (FP-Form A-NS) versus placebo Composite Eyelid Debris, Redness & Discomfort Placebo FP-Form A-NS Baseline (SD) 5.2(1.30) 4.7 (0.82) Day 14 (SD) 3.8(1.48) 2.5 (1.90) Change from Baseline (SD) -1.4(0.55) -2.2(1.62) p values 0.0046 0.0020 FP-Form A-NS vs.
  • Table 14 Composite VAS score of dry eye symptoms: eye dryness, burning-stinging, foreign body sensation, itching, photophobia, pain and blurred vision, at 14 Day of treatment with fluticasone propionate form A nanosuspension of the invention (FP-Form A-NS) versus placebo
  • the nanosuspension composition prepared in example 2 was subjected to storage stability testing by storing the nanosuspension at three different temperatures and humidity conditions (5°C, 25°C / 40% RH; 40°C / 25% RH)
  • the resuspendability of the nanosuspension, the content of fluticasone propionate, the particle size distribution and the content of benzalkonium chloride were assessed at 1 month and 3-month time-points (see results reported in Example 3 and Tables 2 and 3), at 5-month time point at 40 °C (Table 15) up to 12 months at 5°C and 25°C (Table 16).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EP20186965.8A 2019-07-23 2020-07-21 Verfahren zur herstellung steriler ophthalmischer wässriger fluticason-propionat-form-a-nanokristallsuspensionen Active EP3769753B1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
HRP20220165TT HRP20220165T1 (hr) 2019-07-23 2020-07-21 Postupak priprave sterilnih oftalmoloških vodenih suspenzija nanokristala flurikazona-propionata oblika a
PL20186965T PL3769753T3 (pl) 2019-07-23 2020-07-21 Sposób wytwarzania sterylnych oftalmicznych zawiesin wodnych nanokryształów postaci A propionianu flutykazonu
RS20220142A RS62932B1 (sr) 2019-07-23 2020-07-21 Postupak pripreme sterilne nanokristalne suspenzije oftamološkog vodenog flutikazon propionata forme a
SI202030032T SI3769753T1 (sl) 2019-07-23 2020-07-21 Postopek za pripravo sterilnih oftalmičnih vodnih nanokristalnih suspenzij flutikazon propionata oblike A
CY20221100069T CY1124930T1 (el) 2019-07-23 2022-01-27 Διεργασια για την παρασκευη στειρων οφθαλμικων υδατικων εναιωρηματων νανοκρυσταλλων μορφης α προπιονικης φλουτικαζονης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877599P 2019-07-23 2019-07-23
US201962942551P 2019-12-02 2019-12-02

Publications (2)

Publication Number Publication Date
EP3769753A1 true EP3769753A1 (de) 2021-01-27
EP3769753B1 EP3769753B1 (de) 2021-11-17

Family

ID=71738074

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20186965.8A Active EP3769753B1 (de) 2019-07-23 2020-07-21 Verfahren zur herstellung steriler ophthalmischer wässriger fluticason-propionat-form-a-nanokristallsuspensionen

Country Status (21)

Country Link
US (3) US20220241296A1 (de)
EP (1) EP3769753B1 (de)
JP (2) JP7021301B2 (de)
KR (1) KR20220038443A (de)
CN (2) CN111821261B (de)
AU (1) AU2020317084A1 (de)
CA (1) CA3145055A1 (de)
CY (1) CY1124930T1 (de)
DK (1) DK3769753T3 (de)
ES (1) ES2905793T3 (de)
HR (1) HRP20220165T1 (de)
HU (1) HUE057416T2 (de)
LT (1) LT3769753T (de)
MD (1) MD3769753T2 (de)
MX (1) MX2022000928A (de)
PL (1) PL3769753T3 (de)
PT (1) PT3769753T (de)
RS (1) RS62932B1 (de)
SI (1) SI3769753T1 (de)
TW (1) TW202116326A (de)
WO (1) WO2021014348A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021903A1 (en) 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2010148190A1 (en) 2009-06-19 2010-12-23 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
WO2013169647A1 (en) 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20180117064A1 (en) 2015-05-08 2018-05-03 Activus Pharma Co., Ltd. Aqueous suspension agent containing glucocorticosteroid nanoparticles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
US8010032B2 (en) * 2005-05-23 2011-08-30 Xerox Corporation Fuser member comprising deflocculated material
BR112015014262A8 (pt) * 2012-12-17 2019-10-08 Glaxo Group Ltd formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021903A1 (en) 1992-05-06 1993-11-11 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US20060229219A1 (en) * 2005-04-11 2006-10-12 Advanced Medical Optics, Inc. Borate-polyol mixtures as a buffering system
WO2010141834A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2010148190A1 (en) 2009-06-19 2010-12-23 Alcon Research, Ltd. Aqueous pharmaceutical compositions containing borate-polyol complexes
WO2013025696A1 (en) 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation
WO2013169647A1 (en) 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (de) * 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Nanokristalle von Fluticasonpropionat
US20180117064A1 (en) 2015-05-08 2018-05-03 Activus Pharma Co., Ltd. Aqueous suspension agent containing glucocorticosteroid nanoparticles

Also Published As

Publication number Publication date
CN111821261B (zh) 2022-07-26
CN115120557B (zh) 2024-05-07
AU2020317084A1 (en) 2022-03-03
SI3769753T1 (sl) 2022-04-29
CA3145055A1 (en) 2021-01-28
WO2021014348A1 (en) 2021-01-28
MD3769753T2 (ro) 2022-04-30
CN111821261A (zh) 2020-10-27
JP2022062172A (ja) 2022-04-19
US20220323352A1 (en) 2022-10-13
JP7021301B2 (ja) 2022-02-16
US11406596B2 (en) 2022-08-09
JP7494230B2 (ja) 2024-06-03
MX2022000928A (es) 2022-02-22
DK3769753T3 (da) 2022-01-31
US20210023001A1 (en) 2021-01-28
US20220241296A1 (en) 2022-08-04
CN115120557A (zh) 2022-09-30
ES2905793T3 (es) 2022-04-12
EP3769753B1 (de) 2021-11-17
LT3769753T (lt) 2022-05-10
HRP20220165T1 (hr) 2022-04-29
KR20220038443A (ko) 2022-03-28
CY1124930T1 (el) 2023-01-05
RS62932B1 (sr) 2022-03-31
HUE057416T2 (hu) 2022-05-28
PL3769753T3 (pl) 2022-04-04
PT3769753T (pt) 2022-02-15
JP2021017449A (ja) 2021-02-15
TW202116326A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
EP3843704B1 (de) Emulsionsformulierungen von multikinaseinhibitoren
JP5558582B2 (ja) 眼科用医薬組成物の調製方法
US20220323352A1 (en) Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
EP3137481B1 (de) Membranhaftende selbstorganisierende systeme zur behandlung von okularen störungen
EP4194011A1 (de) Herstellung von cyclodextrin-nanopartikeln für ophthalmische wirkstoffabgabe
JP2013508420A (ja) 点眼製剤およびその製造方法
US20040186084A1 (en) Triamcinolone formulations and methods for their preparation and use
TW202114697A (zh) 用於穩定包括藥物的水性組成物之pH值的方法
CN106714803B (zh) 眼用混悬液制剂
EP2827838B1 (de) Ophthalmische pharmazeutische zusammensetzung mit einem carboanhydrasehemmer und verfahren zur herstellung davon
KR102271247B1 (ko) 안과용 현탁액 조성물의 제조방법
EP4248962A1 (de) Augentropfen zur linderung oder prävention von netzhautkreislaufstörungen und erkrankungen im zusammenhang mit retinalen nervenblutgefässen
WO2022195382A1 (en) A stable ophthalmic nanosupension of brinzolamide
JP2024080925A (ja) 網膜循環障害及び網膜神経血管連関障害の改善用又は予防用点眼剤
JP2019163227A (ja) 医薬組成物

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20220165

Country of ref document: HR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210301

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20210301

Extension state: KH

Effective date: 20210301

Extension state: TN

Effective date: 20210301

Extension state: MA

Effective date: 20210301

RAX Requested extension states of the european patent have changed

Extension state: ME

Payment date: 20210301

Extension state: BA

Payment date: 20210301

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/14 20060101AFI20210412BHEP

Ipc: C07J 31/00 20060101ALI20210412BHEP

Ipc: A61P 27/00 20060101ALI20210412BHEP

Ipc: A61K 31/56 20060101ALI20210412BHEP

Ipc: A61K 47/10 20170101ALI20210412BHEP

Ipc: A61K 47/02 20060101ALI20210412BHEP

Ipc: A61K 9/10 20060101ALI20210412BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210611

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: TN

Ref legal event code: VAGR

Ref document number: TN/P/2022/000022

Country of ref document: TN

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020001026

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1447493

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211215

REG Reference to a national code

Ref country code: MA

Ref legal event code: VAGR

Ref document number: 53146

Country of ref document: MA

Kind code of ref document: B1

Ref country code: DK

Ref legal event code: T3

Effective date: 20220128

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3769753

Country of ref document: PT

Date of ref document: 20220215

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20220210

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20220400222

Country of ref document: GR

Effective date: 20220309

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20211117

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2905793

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20220412

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E021985

Country of ref document: EE

Effective date: 20220210

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20220165

Country of ref document: HR

REG Reference to a national code

Ref country code: MD

Ref legal event code: VAGR

Ref document number: 3769753

Country of ref document: MD

Date of ref document: 20220430

Kind code of ref document: T2

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E057416

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220165

Country of ref document: HR

Payment date: 20220707

Year of fee payment: 3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020001026

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220818

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20220719

Year of fee payment: 3

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1447493

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211117

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230404

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230627

Year of fee payment: 4

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220165

Country of ref document: HR

Payment date: 20230627

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20230629

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230712

Year of fee payment: 4

Ref country code: RO

Payment date: 20230705

Year of fee payment: 4

Ref country code: IT

Payment date: 20230731

Year of fee payment: 4

Ref country code: ES

Payment date: 20230801

Year of fee payment: 4

Ref country code: CY

Payment date: 20230627

Year of fee payment: 4

Ref country code: CH

Payment date: 20230801

Year of fee payment: 4

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: TN

Payment date: 20220731

Year of fee payment: 3

Ref country code: MD

Payment date: 20230711

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20230628

Year of fee payment: 4

Ref country code: SE

Payment date: 20230720

Year of fee payment: 4

Ref country code: RS

Payment date: 20230704

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230704

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20230707

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230705

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240628

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240621

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240625

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HR

Payment date: 20240624

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240626

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20240620

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240626

Year of fee payment: 5

Ref country code: EE

Payment date: 20240620

Year of fee payment: 5

Ref country code: BG

Payment date: 20240627

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240620

Year of fee payment: 5

Ref country code: PT

Payment date: 20240627

Year of fee payment: 5

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20220165

Country of ref document: HR

Payment date: 20240624

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240709

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240625

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240710

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240715

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20240722

Year of fee payment: 5

Ref country code: DE

Payment date: 20240729

Year of fee payment: 5

Ref country code: MC

Payment date: 20240729

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240730

Year of fee payment: 5

VSFP Annual fee paid to validation state [announced via postgrant information from national office to epo]

Ref country code: MD

Payment date: 20240708

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240723

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240715

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240716

Year of fee payment: 5